Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28429276 | 0.90 | TLR7 (0.34) | TLR7 | |
| SCHEMBL28387675 | 0.81 | MGMT (0.32) | — | |
| SCHEMBL1254741 | 0.79 | TLR7 (0.51) | TLR7 | |
| SCHEMBL28386004 | 0.79 | ALDH1A1 (0.37) | TLR7 | |
| SCHEMBL1829942 | 0.76 | HASPIN (0.44) | TLR7 | |
| SCHEMBL7480837 | 0.75 | TLR7 (0.43) | TLR7 | |
| SCHEMBL10074072 | 0.75 | HASPIN (0.40) | TLR7 | |
| SCHEMBL11780377 | 0.71 | MAPT (0.36) | TLR7 | |
| SCHEMBL16019753 | 0.71 | TLR7 (0.47) | TLR7 | |
| SCHEMBL29121458 | 0.70 | PTGER4 (0.34) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105481922-B | Preparation method of cangrelor intermediate | 上海勋和医药科技有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-RE46276-E1 | Triazolo(4,5-D)pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2017-01-17 | — | — | US | disclosed |
| US-20150152111-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA UK LIMITED (GB) | 2015-06-04 | — | — | US | disclosed |
| US-20130109702-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA AB (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130072503-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA (GB) | 2013-03-21 | — | — | US | disclosed |
| US-20120165348-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| EP-1386917-B1 | Intermediates for the preparation of certain triazolopyrimidines as P2T antagonists | ASTRAZENECA AB (SE) | 2011-06-22 | — | — | EP | disclosed |
| EP-2322513-A2 | Intermediates | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100069408-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| US-20080214812-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20030144305-A1 | Novel compounds | ASTRAZENECA AB | 2003-07-31 | — | — | US | disclosed |
| US-6525060-B1 | P2T (P2YADP or P2TAC) receptor antagonists; anticoagulant, antithrombotic | ASTRAZENECA UK LIMITED (GB) | 2003-02-25 | — | — | US | disclosed |
| EP-0840740-B1 | NEW INHIBITORS OF PLATELET AGGREGATION | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | EP | disclosed |
| EP-0946561-B1 | TRIAZOLO(4,5-D)PYRIMIDINYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| US-6297232-B1 | TREATMENT OF PLATELET AGGREGATION DISORDERS. | ASTRAZENECA AB (SE) | 2001-10-02 | — | — | US | disclosed |
| EP-1135391-A1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000034283-A1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-06-15 | — | — | WO | disclosed |
| EP-0946561-A1 | TRIAZOLO(4,5-D)PYRIMIDINYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | Astra Pharmaceuticals Limited (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028300-A1 | TRIAZOLO[4,5-D]PYRIMIDINYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-07-02 | — | — | WO | disclosed |
| US-5747496-A | Inhibitors of platelet aggregation | ASTRA PHARMACEUTICALS LIMITED (GB) | 1998-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165348-A1 | Novel compounds | P2RX5, P2RX4, P2RY4 | TLR7 719/4885 |
| US-20150152111-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | TLR7 2134/4885 |
| US-20080214812-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | THPO, PF4, P2RY4 | TLR7 2134/4885 |
| US-20100069408-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | THPO, PF4, P2RY4 | TLR7 2134/4885 |
| US-20030144305-A1 | Novel compounds | DPYD, TYMP, NUDT15 | TLR7 947/4885 |
| US-20130072503-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | TLR7 2134/4885 |
| US-20130109702-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | TLR7 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.